NCT04641455

Use of Mucolytic Solution Before Upper Endoscopy

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Vitkovice Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study was designed to evaluate the effectiveness of the maximum dose of mucolytic solution used before upper endoscopy on the visibility of the gastric mucosa

Detailed description

Residual gastric content containing mucus, bubbles, bile and food particles may limit visibility of gastric mucosa and therefore diagnostic yield of upper endoscopy, especially in cases of early neoplastic lesions. Data on benefit of peroral mucolytic solution administered before upper endoscopy are limited.

Conditions

• Gastric Cancer
• Gastroscopy

Interventions

Type	Name	Description
DRUG	Espumisan, N acetylcystein	Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
DRUG	Espumisan, N acetylcystein	Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
DRUG	Water	Administration of water before upper endoscopy

Timeline

• Start date: 2020-12-01
• Primary completion: 2021-05-30
• Completion: 2021-06-30
• First posted: 2020-11-23
• Last updated: 2020-11-23

Locations

1 site across 1 country: Czechia